ArticleOligonucleotides2011
T-oligos inhibit growth and induce apoptosis in human ovarian cancer cells.
Article in Oligonucleotides, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 43 citations in OpenAlex.
- G-quadruplex topologies determine the functional outcome of guanine-rich bioactive oligonucleotides.Nucleic acids research · 2025Article
- Beginning at the ends: telomere and telomere-based cancer therapeutics.Molecular genetics and genomics : MGG · 2024Review
- Brain Tumors: Development, Drug Resistance, and Sensitization - An Epigenetic Approach.Epigenetics · 2023Review
- Deciphering the Functions of Telomerase Reverse Transcriptase in Head and Neck Cancer.Biomedicines · 2023Review
- Shelterin complex gene: Prognosis and therapeutic vulnerability in cancer.Biochemistry and biophysics reports · 2021Review
- Review
- New findings showing how DNA methylation influences diseases.World journal of biological chemistry · 2019Article
- Review
- Effect of therapies-mediated modulation of telomere and/or telomerase on cancer cells radiosensitivity.Oncotarget · 2018Review
- Genetic variants in telomere-maintenance genes are associated with ovarian cancer risk and outcome.Journal of cellular and molecular medicine · 2017Article
- Role of Epigenetics in Uveal Melanoma.International journal of biological sciences · 2017Review
- Telomere and Telomerase Therapeutics in Cancer.Genes · 2016Review
- A Comparative Analysis of Genetic and Epigenetic Events of Breast and Ovarian Cancer Related to Tumorigenesis.International journal of molecular sciences · 2016Review
- Star-shaped tetraspermine enhances cellular uptake and cytotoxicity of T-oligo in prostate cancer cells.Pharmaceutical research · 2015Article
- Drug resistance in cancer: an overview.Cancers · 2014Review
- Non-small cell lung cancer is susceptible to induction of DNA damage responses and inhibition of angiogenesis by telomere overhang oligonucleotides.Cancer letters · 2014Article
- Novel delivery system for T-oligo using a nanocomplex formed with an alpha helical peptide for melanoma therapy.International journal of nanomedicine · 2014Article
- Use of epigenetic drugs in disease: an overview.Genetics & epigenetics · 2014Review
- Beyond Telomerase: Telomere Instability as a Novel Target for Cancer Therapy.Journal of molecular and genetic medicine : an international journal of biomedical research · 2013Article
- Cancer development, progression, and therapy: an epigenetic overview.International journal of molecular sciences · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Ovarian cancer remains a leading cause of death among women worldwide, and current treatment regimens for advanced disease are inadequate. Oligonucleotides with sequence homology to telomeres (called T-oligos) have been shown to mimic DNA damage responses in cells and induce cytotoxic effects in certain tumor cell lines. We studied the effects of 2 distinct 16 mer T-oligos in 4 human ovarian epithelial carcinoma cell lines. A T-oligo with perfect homology to the telomere overhang region demonstrated some cytotoxic activity in half of the cell lines. A G-rich T-oligo derivative showed more potency and broader cytotoxic activity in these lines than the parental T-oligo. Activation of apoptotic pathways in ovarian cancer cells by exposure to the T-oligo was demonstrated by multiple independent assays. T-oligo was shown to have additive, or more than additive, activity in combination with 2 different histone deacetylase drugs currently in clinical testing. T-oligos may therefore provide a new and tumor-targeted approach to ovarian cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.